Project Grant HT94252310820
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$907K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $807,400.00 to the Provincial Health Services Authority (BC Cancer) in Canada. The grant, awarded on May 1, 2024, supports a research project titled "DECODING HOW DISTINCT MECHANISMS OF GENOMIC INSTABILITY FOUND IN TNBC PATIENTS PROGRAM THE TISSUE MICROENVIRONMENT AND THERAPY RESPONSE AT METASTATIC SITES." This project aims to investigate...
This $439,912 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Provincial Health Services Authority, operating as BC Cancer, a major Canadian healthcare organization specializing in cancer research, treatment, and prevention. The grant aims to "HARNESSING THE IMMUNE RESPONSE IN EXCEPTIONALLY LONG-TERM SURVIVORS TO DEVELOP NOVEL THERAPEUTICS", leveraging BC Cancer's expertise...
The U.S. Defense Health Agency awarded a $109,895 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Provincial Health Services Authority (operating as BC Cancer) in Canada. The grant is for the purpose of "DEVELOPING FIRST-IN-KIND PRECLINICAL MODELS OF PRIMARY TESTICULAR LYMPHOMA" over a 2-year period from September 1, 2024 to August 31, 2026. As a prominent Canadian healthcare organization specializing in cancer research, treatment, and...
The federal Project Grant award of $438,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by the Provincial Health Services Authority in Canada, operating under the name BC Cancer, to decode and target genomic instability in pediatric osteosarcoma. The project, with a period of performance from September 30, 2023 to September 29, 2025, aims to develop innovative solutions for cancer treatment,...
This Project Grant award of $508,747.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the "THE OVARIAN CANCER OBSERVATORY: PREVENTION, IMPACT, AND LEARNING FROM OPPORTUNISTIC SALPINGECTOMY" research project conducted by the Provincial Health Services Authority (operating as BC Cancer) in Canada. Through this multi-year (Sep 1, 2023 - Aug 31, 2027) grant, BC Cancer will perform biomedical research to develop...
The Department of Defense's Defense Health Agency awarded a $1,173,081 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, for the program titled "TARGETING EPIDERMAL PLASTICITY TO PREVENT TRIPLE NEGATIVE BREAST CANCER RECURRENCE". The grant, which runs from April 1, 2025 to March 31, 2029, is funded through the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research aimed at...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The $1,050,767 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University Health Network (UHN) to investigate therapeutic targeting of genomic instability in triple negative breast cancer. The research will be conducted at UHN's location in Ottawa, Ontario over a 3-year period from September 2023 to September 2026. This funding supports UHN's ongoing biomedical and clinical research...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $961,900.00 to Virginia Commonwealth University (VCU) for the Early Detection of Cancer Disparity and Treatment Resistance in TNBC project. The 3-year award, effective February 1, 2024, supports research to advance early detection and treatment of triple-negative breast cancer (TNBC), which disproportionately impacts minority populations. The funding will enable...
This federal Project Grant award of $480,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by Baylor College of Medicine in Houston, Texas to investigate "TARGETING CRYPTIC SPLICING-DERIVED NEOANTIGENS IN HNRNPM-DYSREGULATED TRIPLE-NEGATIVE BREAST CANCER". The project aims to transform healthcare for military service members, veterans, and the broader public through...